ChemoCentryx (Nasdaq:CCXI) announced financial results for the fourth quarter and full year ended December 31, 2017 and provided an overview of the Company’s recent corporate highlights. As quoted in the press release: ChemoCentryx’s Phase III ADVOCATE pivotal trial of avacopan for the treatment of ANCA vasculitis has 200 sites activated and 220 patients enrolled to …

ChemoCentryx (Nasdaq:CCXI) announced financial results for the fourth quarter and full year ended December 31, 2017 and provided an overview of the Company’s recent corporate highlights.

As quoted in the press release:

ChemoCentryx’s Phase III ADVOCATE pivotal trial of avacopan for the treatment of ANCA vasculitis has 200 sites activated and 220 patients enrolled to date. The trial will evaluate the safety and efficacy of avacopan following 52 weeks of treatment and will include approximately 300 patients. In addition to testing the effect of avacopan on improving active vasculitis, the ADVOCATE trial will also test avacopan’s efficacy in preventing the recurrence of vasculitis, one of the major limitations of the current standard of care for patients with ANCA vasculitis.

Click here to read the full press release.